p21、p53与肝细胞癌临床病理特性及预后的关系研究  

STUDY OF RELATIONSHIP BETWEEN CLINICAL PATHOLOGICAL CHARACTER AND PROGNOSIS OF HEPATOCELLULAR CARCINOMA AND EXPRESSION OF p21 AND p53

作　　者：覃晓[1] 林进令[1] 黎乐群[1] 马韵[2] 梁水庭[1] 陆云飞[1] 

机构地区：[1]广西医科大学第一附属医院外科,南宁530021 [2]广西医科大学病理学教研室

出　　处：《广西医科大学学报》2002年第3期317-319,共3页Journal of Guangxi Medical University

摘　　要：目的 :探讨原癌基因 p2 1(p2 1)、抑癌基因 p5 3(p5 3)的表达与肝细胞癌 (HCC)临床病理特性和预后之间的关系。方法 :应用免疫组化方法 ,检测 6 3例 HCC标本中 p2 1和 p5 3的表达。结果 :p2 1阳性表达与 p2 1阴性的 HCC患者术后≥ 5年生存率比较无显著性差异 (P >0 .0 5 ) ;p5 3阳性表达患者术后≥ 5年生存率明显低于 p5 3阴性者 (P <0 .0 0 1) ;p2 1的阳性表达与肿瘤大小、病理类型、分化程度、血清 HBs Ag及 AFP水平之间的关系比较无显著性差异 (P >0 .0 5 )。p5 3阳性表达多见于肿块较大、分化较差的 HCC。结论 :p5 3可作为判断 HCC预后的指标 ,p2 1不能单独作为判断 HCC预后的指标 ,但其与 p5Objectire: To study the relationship between the expression of p21 and p53 in hepatocellular carcinoma(HCC) and its clinical pathological character and prognosis Methods: 63 cases of HCC from Guangxi were applied to detecte the expression of p21 and p53 with immunohistochemical method Results: There was not significant difference between the p21 positive and negative cases in the 5 years survival rate (P>0 05), The 5 years survival rate of the p53 positive cases was lower than that of the p53 negative cases (P<0 001) The expression of p21 was not related to the tumor size,cell differentiation,serum HBsAg and serum AFP level The expression of p53 was higher in large tumor and lower cell differentiation HCC Conclusions: p53 can be used as a marker which can judge the prognosis of HCC p21 can not serve as a prognosis marker alone but may be referred when detected together with p53

关 键 词：P21 P53 肝细胞癌 临床病理特性 预后 免疫组织化学 

分 类 号：R735.7[医药卫生—肿瘤]